Search Results

You are looking at 1 - 10 of 246 items for :

  • "combination therapy" x
Clear All
Full access

reviews current endocrine treatment strategies and recent and ongoing studies of combination therapies in metastatic HR+, HER2-negative (HER2−) breast cancer. ET The estrogen receptor (ER) plays a fundamental role in the development and progression

Full access

Alison K. Conlin and Andrew D. Seidman

; 20 : 4150 – 4159 . 13. O'Shaughnessy J Miles D Vukelja S . Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results . J Clin Oncol

Full access

Meena A. Prasad and Laura M. Kulik

results. Table 3 Combination Therapy: Locoregional Therapy With Angiogenesis Inhibition With the increasing clinical experience with TARE, unexpected observations have been made, including the concept of radiation segmentectomy (≤2 segments

Full access

Mary Cianfrocca and William J. Gradishar

metastatic breast cancer . Cochrane Database Syst Rev 2005 ; CD003372 . 3. O'Shaughnessy J Miles D Vukelja S . Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast

Full access

David A. Reardon, Scott Turner, Katherine B. Peters, Annick Desjardins, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, James E. Herndon II, Lee W. Jones, John P. Kirkpatrick, Allan H. Friedman, James J. Vredenburgh, Darell D. Bigner and Henry S. Friedman

proteinuria (11%). The frequency of grade 3 hypertension increased significantly at doses of 4 mg/kg or greater. Table 2 Published Series of Bevacizumab as a Single-Agent and in Combination Therapy for Adults With Recurrent Glioblastoma Maximal

Full access

Tanya E. Keenan and Sara M. Tolaney

outcomes with current standard-of-care regimens. 12 Table 3. Anti–PD-1/L1 Combination Therapy Trials in Early-Stage TNBC Most recently, the NeoTRIPaPDL1 trial (NCT02620280) of atezolizumab added to neoadjuvant carboplatin plus nab-paclitaxel followed by

Full access

Noa Efrat Ben-Baruch, Ron Bose, Shyam M. Kavuri, Cynthia X. Ma and Matthew J. Ellis

report describes the first case of a HER2 -mutated breast cancer that clinically benefited from neratinib monotherapy. When this patient's cancer progressed, she was placed on neratinib plus capecitabine combination therapy and she again experienced

Full access

Anastasia Drobysheva, Laura J. Klesse, Daniel C. Bowers, Veena Rajaram, Dinesh Rakheja, Charles F. Timmons, Jason Wang, Korgun Koral, Lynn Gargan, Erica Ramos and Jason Y. Park

-dabrafenib; these images show progressive increase in tumor burden (white arrows). (G) Sagittal T1-weighted with gadolinium image obtained after 3 months of combination therapy with dabrafenib at 50 mg and trametinib at 0.5 mg daily (9 months of targeted therapy

Full access

Michelle T. Ashworth and Adil Daud

monotherapy, PET/CT showed new hypermetabolic nodules, one in the mesentery and one in the right leg. The patient was enrolled onto a second clinical trial of combination therapy with the BRAF and MEK inhibitors vemurafenib and GDC-0973. This treatment was

Full access

Tayyaba Hasan

reduction in tumor burden achieved with the combination therapy was synergistic relative to the individual monotherapies, cetuximab alone, or PDT alone ( P < .001; analysis of variance; error bars represent standard error of the mean). Adapted from del